Johns Hopkins ABX Guide
Ketoconazole
INDICATIONS
FDA
FDA
- Ketoconazole tablets
- Treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
- Note: despite FDA approval, due to the potential for severe hepatitis, adrenal insufficiency, and drug-drug interactions, systemic ketoconazole should not be used as a first-line treatment for any fungal infections. Additionally, it should not be used for the treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections.
- Treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
- Ketoconazole cream 2%
- Treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum
- Treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare)
- Treatment of cutaneous candidiasis caused by Candida spp.
- Treatment of seborrheic dermatitis.
- Ketoconazole shampoo 2%
- Treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare).
- Ketoconazole foam 2%
- Treatment of seborrheic dermatitis in immunocompetent patients ≥12 years old
- Levoketoconazole tablets
- Treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative.
- Not approved for fungal infections.
- Treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of hyperadrenalism
- Booster for calcineurin inhibitor to increase levels in solid organ transplant recipients
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 11, 2026
Citation
Tsai, Y. V, and Edina Avdic. "Ketoconazole." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, hopkinsguides.org/hopkins/view/Johns_Hopkins_ABX_Guide/540300/all/Ketoconazole.
Tsai YV, Avdic E. Ketoconazole. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://hopkinsguides.org/hopkins/view/Johns_Hopkins_ABX_Guide/540300/all/Ketoconazole. Accessed October 14, 2026.
Tsai, Y. V., & Avdic, E. (2026). Ketoconazole. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://hopkinsguides.org/hopkins/view/Johns_Hopkins_ABX_Guide/540300/all/Ketoconazole
Tsai YV, Avdic E. Ketoconazole [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 October 14]. Available from: https://hopkinsguides.org/hopkins/view/Johns_Hopkins_ABX_Guide/540300/all/Ketoconazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ketoconazole
ID - 540300
A1 - Tsai,Y.,Pharm.D.
AU - Avdic,Edina,Pharm.D.
Y1 - 2026/10/11/
BT - Johns Hopkins ABX Guide
UR - https://hopkinsguides.org/hopkins/view/Johns_Hopkins_ABX_Guide/540300/all/Ketoconazole
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
